Engineered renal tissue as a potential platform for pharmacokinetic and nephrotoxicity testing

Area of Science:

• Pharmacology
• Regenerative Medicine
• Toxicology

Background:

• Drug-induced kidney toxicity is a significant challenge in pharmaceutical development.
• Current in vitro models using 2D cell cultures have limitations in predicting human nephrotoxicity accurately.
• Animal models often fail to reliably predict human responses to drug toxicity.

Purpose of the Study:

• To review the potential of regenerative medicine techniques for engineering human organoids for drug screening.
• To highlight the application of these organoids in assessing nephrotoxicity.
• To discuss advancements in creating more realistic in vitro models for drug development.

Main Methods:

• Utilizing regenerative medicine strategies to engineer human organoids.
• Exploring collagen-based culture systems to promote 3D tubule formation of kidney cells.
• Investigating the development of functional 'mini-kidneys' from stem cell suspensions.

Main Results:

• Regenerative medicine offers novel approaches to create advanced in vitro models for drug testing.
• 3D culture systems, such as tubule formation and mini-kidneys, show promise for improved realism.
• Engineered mini-kidneys represent a highly realistic model for evaluating drug effects on kidney function.

Conclusions:

• Regenerative medicine techniques are crucial for developing advanced human organoid models for drug screening.
• Engineered mini-kidneys hold significant potential for accurate prediction of drug nephrotoxicity.
• These advanced models can enhance the safety and efficacy assessment of pharmaceuticals.